Clinical Trials Directory

Trials / Unknown

UnknownNCT02875990

Characterization of Immunosuppressive Signing of Cervical Cancer

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Assistance Publique Hopitaux De Marseille · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Infection with Human Papillomavirus high-risk Human (HR-HPV) is the main factor of risk of cancer of the cervix. Recent studies show that cancers linked to infection with HR-HPV are associated with immunosuppression and lack of T cell response Such mechanisms would promote progression to cancer and progression of it . Various factors such as an increase of regulatory T cells, the presence of myeloid cells and suppressor of defects in the signaling pathway Toll Like Receptor (TLR) may have a key role in these immunosuppression mechanisms. At this stage of knowledge, a better characterization of local and systemic immunosuppressive signing of cervical cancer is needed. The results should have a significant medical impact for the identification of new prognostic markers and new therapeutic targets for the treatment of patients with cervical cancer. The aim of this research project is to define the signing of immunosuppressive cancer cervix and analyze the different mechanisms involved in this immunosuppression.

Conditions

Interventions

TypeNameDescription
BIOLOGICALBlood sample

Timeline

Start date
2016-09-01
Primary completion
2024-09-01
Completion
2024-09-01
First posted
2016-08-23
Last updated
2016-08-23

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02875990. Inclusion in this directory is not an endorsement.